Long Term Safety of Vildagliptin (100mg qd) In Patients With Type 2 Diabetes

A Multicenter, Open, Long Term Safety Study of 52 Weeks Treatment With Vildagliptin (100 mg qd) In Patients With Type 2 Diabetes (Extension Study of Study CLAF237A1303)

This 52-week multicenter open-labeled extension study is designed to assess the long-term safety of vildagliptin (100 mg qd) in patients with Type 2 Diabetes. This extension study is open to patients who have completed core study CLAF237A1303.

Inclusion Criteria:

• Diagnosis as Type 2 Diabetes
• Patients who have completed study CLAF237A1303
• Outpatients

Exclusion Criteria:

• Patients who prematurely discontinued Study CLAF237A1303
• Other protocol-defined inclusion/exclusioncriterial may apply